Researchers say discovery could establish the basis for a novel, tandem biomarker-peptide therapeutic approach to schizophrenia.

New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...

Current schizophrenia medications treat symptoms such as hallucinations and delusions, but do little for cognitive symptoms like disorganized thinking or executive dysfunction. As a result, many ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...